TORONTO, Sept. 11 /CNW/ - Novo Nordisk ranks as best-in-class in
healthcare - one of 18 global supersectors - in Dow Jones Sustainability
Indexes, the world's leading indexes for sustainability-driven investment
portfolios. This ranking, effective at the opening of equity markets on
24 September 2007, is a result of the latest global analysis of corporate
sustainability leadership, based on a thorough analysis of companies'
economic, environmental and social performance.
The analysis concludes that "Novo Nordisk is the leading company in terms
of sustainability in the pharmaceutical industry. Sustainability is an
integral part of its corporate strategy and business organisation." Novo
Nordisk's performance is found to be particularly strong in the social
dimension - human capital development, corporate citizenship/philanthropy,
social reporting, animal testing and bioethics. Also the company's responsible
sourcing, environmental management and climate strategy achieve high scores.
"This rating is important for us. Our ambition is to be the leading
healthcare company in terms of sustainability, and we regard the ranking in
Dow Jones Sustainability Indexes as recognition of the results we have
achieved so far," says Lise Kingo, executive vice president and chief of
staffs, Novo Nordisk.
The indexes, which currently comprise USD 5.6 billion assets under
management, are used as a tool by asset managers in 15 countries to guide
their investment decisions.
The Dow Jones Sustainability Indexes follow a best-in-class approach and
include the sustainability leaders from each industry on a global and regional
level, respectively. The annual review is based on a thorough analysis of
corporate economic, environmental and social performance, assessing issues
such as corporate governance, risk management, branding, climate change,
supply chain standards and labour practices.
Novo Nordisk has been a component of the Dow Jones Sustainability Indexes
every year since the launch in 1999.
Novo Nordisk is a healthcare company and a world leader in diabetes care.
The company has a broad diabetes product portfolio, including advanced
products within the area of insulin delivery systems. In addition, Novo
Nordisk has a leading position within areas such as haemostasis management,
growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 25,350 employees
in 79 countries, and markets its products in 179 countries. Novo Nordisk's B
shares are listed on the stock exchanges in Copenhagen and London. Its ADRs
are listed on the New York Stock Exchange under the symbol 'NVO'. For more
information, visit novonordisk.com.
For further information:
For further information: Media: Outside North America: Michael Laub,
Tel: (+45) 4442 1960, firstname.lastname@example.org; In North America: Sean Clements,
Tel: (609) 514-8316, email@example.com; Investors: Outside North America:
Mads Veggerby Lausten, Tel: (+45) 4443 7919, firstname.lastname@example.org; Hans
Rommer, Tel: (+45) 4442 4765, email@example.com; In North America:
Christian Qvist Frandsen, Tel: (609) 919-7937, firstname.lastname@example.org